Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 619 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Malignant Soft Tissue Neoplasm Clear all
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Sarcoma
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced May 21, 2026, 7:22 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Lymphoma
Interventions
cryopreservation
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2011
U.S. locations
82
States / cities
Anchorage, Alaska • Atlanta, Georgia • Austell, Georgia + 51 more
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced May 21, 2026, 7:22 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
regorafenib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Santa Monica, California • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced May 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
172
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 7:22 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
oxaliplatin, etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2014 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Mifepristone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
Interventions
TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg, TB-403 175mg/kg
Drug
Lead sponsor
Oncurious NV
Industry
Eligibility
6 Months to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
10
States / cities
Little Rock, Arkansas • Oakland, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced May 21, 2026, 7:22 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage III Adult Soft Tissue Sarcoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Melanoma
Interventions
isolated limb perfusion, melphalan, quality-of-life assessment
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced May 21, 2026, 7:22 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Ewing Sarcoma
Interventions
Xaluritamig
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 7:22 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
fludarabine, cyclophosphamide, cetuximab, FGFR4-CAR T Cells
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 39 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Sarcoma
Interventions
trabectedin
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
32
States / cities
Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
Interventions
Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Pineoblastoma, Primary Central Nervous System Neoplasm, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
Interventions
Adavosertib, Irinotecan Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced May 21, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, doxorubicin hydrochloride, mitomycin C
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced May 21, 2026, 7:22 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 7:22 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Sarcoma
Interventions
NY-ESO-1 peptide vaccine, sargramostim
Biological
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma
Interventions
Laboratory Biomarker Analysis, Nelfinavir Mesylate
Other · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Miami, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced May 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Cancer
Interventions
Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Months to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced May 21, 2026, 7:22 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced May 21, 2026, 7:22 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Interventions
VAL-413, Temozolomide
Drug
Lead sponsor
Valent Technologies, LLC
Industry
Eligibility
1 Year to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 7:22 PM EDT